Since the BRAF + MEK inhibitor combination is what the National Health Insurance Fund reimburses in Hungary for the first-line treatment of BRAF mutant advanced melanoma, 97.5% of the patients included in the study received targeted therapy in the first line. The gene discussed is MAP2K7; the disease is melanoma.